8OV1
| SARS-CoV-2 nsp10-16 methyltransferase in complex with ADP | Descriptor: | 1,2-ETHANEDIOL, 2'-O-methyltransferase nsp16, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, ... | Authors: | Kremling, V, Sprenger, J, Oberthuer, D. | Deposit date: | 2023-04-25 | Release date: | 2023-05-10 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (1.67 Å) | Cite: | SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery Elife, 2024
|
|
8OV3
| SARS-CoV-2 nsp10-16 methyltransferase in complex with 5-Iodotubercidin | Descriptor: | (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL, 1,2-ETHANEDIOL, 2'-O-methyltransferase nsp16, ... | Authors: | Kremling, V, Sprenger, J, Oberthuer, D. | Deposit date: | 2023-04-25 | Release date: | 2023-05-10 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (1.82 Å) | Cite: | SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery Elife, 2024
|
|
8OT0
| SARS-CoV-2 nsp10-16 methyltransferase in complex with MTA and glycine | Descriptor: | 1,2-ETHANEDIOL, 2'-O-methyltransferase nsp16, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, ... | Authors: | Kremling, V, Sprenger, J, Oberthuer, D, Falke, S. | Deposit date: | 2023-04-20 | Release date: | 2023-05-10 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (2.21 Å) | Cite: | SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery Elife, 2024
|
|
8OV2
| SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin | Descriptor: | 1,2-ETHANEDIOL, 2'-O-methyltransferase nsp16, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, ... | Authors: | Kremling, V, Sprenger, J, Oberthuer, D. | Deposit date: | 2023-04-25 | Release date: | 2023-05-10 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (1.86 Å) | Cite: | SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery Elife, 2024
|
|